Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Common Equity: 2010-2025

Historic Common Equity for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $22.0 million.

  • Lineage Cell Therapeutics' Common Equity fell 65.98% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 65.98%. This contributed to the annual value of $78.4 million for FY2024, which is 23.59% up from last year.
  • Lineage Cell Therapeutics' Common Equity amounted to $22.0 million in Q3 2025, which was down 54.45% from $48.4 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Common Equity peaked at $124.7 million during Q2 2021, and registered a low of $22.0 million during Q3 2025.
  • Moreover, its 3-year median value for Common Equity was $66.9 million (2024), whereas its average is $63.7 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Common Equity surged by 32.26% in 2021 and then slumped by 65.98% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Common Equity (Quarterly) stood at $92.2 million in 2021, then fell by 20.47% to $73.3 million in 2022, then dropped by 13.53% to $63.4 million in 2023, then climbed by 23.59% to $78.4 million in 2024, then tumbled by 65.98% to $22.0 million in 2025.
  • Its Common Equity was $22.0 million in Q3 2025, compared to $48.4 million in Q2 2025 and $79.0 million in Q1 2025.